Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3666-3674

  Zhang, Guoqing ^a   Cai, Fangping ^b   Zhou, Zhiyong ^a   DeVos, Joshua ^a   Wagar, Nick ^a   Diallo, Karidia ^a   Zulu, Isaac ^c   Wadonda Kabondo, Nellie ^d   Stringer, Jeffrey S A ^e,f   Weidle, Paul J ^g   Ndongmo, Clement B ^c   Sikazwe, Izukanji ^h   Sarr, Abdoulaye ^d   Kagoli, Matthew ⁱ   Nkengasong, John ^a   Gao, Feng ^b   Yang, Chunfu ^a  

^a International Laboratory Branch   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CDC Zambia   (Zambia)

^d CDC Malawi ^*  (Malawi)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h MINISTRY OF HEALTH   (Zambia)

ⁱ MINISTRY OF HEALTH   (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLASMID DNA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ALLELE; ARTICLE; ASSAY; CONTROLLED STUDY; GENE LOCUS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIMIT OF DETECTION; MULTIPLEX ALLELE SPECIFIC ASSAY; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PYROSEQUENCING; RNA STRUCTURE; SEQUENCE ANALYSIS; VIRUS CLASSIFICATION; WILD TYPE;

DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROARRAY ANALYSIS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA;

EID: 84886569625     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01669-13     Document Type: Article

References (41)

1. WHO.2012.WHOHIV drug resistance report 2012.World Health Organization, Geneva, Switzerland.http://www.who.int/hiv/pub/drugresistance/report2012/en/.
2. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, Mahle KC, Heneine W, Johnson JA, Hall HI, Variant, Atypical, and Resistant HIV Surveillance Group.2010.Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.AIDS 24:1203-1212.
3. Stadeli KM, Richman DD.2013.Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.Antivir.Ther.18: 115-123.
4. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF, PharmAccess African Studies to Evaluate Resistance (PASER).2011.HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.Lancet Infect.Dis.11:750-759.
5. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SL, Schaefer M, Papathanasopoulos MA, Stevens W, Gilmour J, IAVI Early Infection Cohort Study Group.2011.Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in east and southern Africa.AIDS Res. Hum. Retroviruses 27:5-12.
6. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM.2010.Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.PLoS One 5:e15510.doi:10.1371/journal.pone.0015510.
7. Wood E, Montaner JS.2011.Time to get serious about HIV antiretroviral resistance.Lancet Infect.Dis.11:723-724.
8. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF.2011.HIV-1- resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.Lancet Infect.Dis.11:769-779.
9. Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriëns J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S.2012.Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.Clin. Infect. Dis.54(Suppl 4):S245-S249.
10. WHO.2012.World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance 2012.World Health Organization, Geneva, Switzerland.http://www.who.int/hiv/pub/drugresistance/drug-resistance-strategy/ en/index.html.
11. Eshleman SH, Crutcher G, Petrauskene O, Kunstman K, Cunningham SP, Trevino C, Davis C, Kennedy J, Fairman J, Foley B, Kop J.2005.Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI Prism 3100 genetic analyzer.J. Clin. Microbiol.43:813-817.
12. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Jr, Reid C, Morgan GF, Winslow DL.2003.Accuracy of the TRUGENE HIV-1 genotyping kit.J. Clin. Microbiol.41:1586-1593.
13. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim S, Wadonda-Kabondo N, Aberle-Grasse J, Kibuka T, Ndumbe PM, Vedapuri S, Zhou Z, Chilima B, Nkengasong JN.2010.Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance.J. Clin. Microbiol.48:3158-3164.
14. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J, Yang C.2011.Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.PLoS One 6:e28184.doi:10 .1371/journal.pone.0028184
15. Buckton AJ, Bissett SL, Myers RE, Beddows S, Edwards S, Cane PA, Pillay D.2008.Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance.J. Antimicrob. Chemother.62:1191-1198.
16. Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH.2012.Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance.PLoS One 7:e36494.doi:10.1371/journal.pone.0036494.
17. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ, Terry Beirn Community Programs for Clinical Research on AIDS.2009.Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.J. Infect. Dis.199:693-701.
18. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW.2007. Characterization of mutation spectra with ultradeep pyrosequencing: application to HIV-1 drug resistance.Genome Res.17:1195-1201.
19. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F.2007.Detection of minor drug-resistant populations by parallel allele-specific sequencing.Nat. Methods 4:123-125.
20. Liu J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, Hazuda DJ, Gao F.2011.Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.Antimicrob. Agents Chemother.55:1114-1119.
21. Church JD, Towler WI, Hoover DR, Hudelson SE, Kumwenda N, Taha TE, Eshleman JR, Eshleman SH.2008.Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.AIDS Res. Hum. Retroviruses 24:595-605.
22. Johnson JA, Li JF, Wei X, Lipscomb J, Bennett D, Brant A, Cong ME, Spira T, Shafer RW, Heneine W.2007.Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations.PLoS One 2:e638.doi:10.1371/journal.pone.0000638.
23. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W.2008.Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy.PLoS Med.5:e158.doi:10.1371/journal.pmed.0050158.
24. Metzner KJ, Rauch P, Walter H, Boesecke C, Zöllner B, Jessen H, Schewe K, Fenske S, Gellermann H, Stellbrink HJ.2005.Detection of minor populations of drug-resistant HIV-1 in acute seroconverters.AIDS 19:1819-1825.
25. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Gunthard HF, Cavassini M.2009.Minority quasispecies of drugresistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.Clin. Infect. Dis.48:239-247.
26. Bansal V, Metzner KJ, Niederöst B, Leemann C, Böni J, Günthard HF, Fehr JS.2011.Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant.Emerg. Infect. Dis.17: 1966-1968.
27. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH.2005.Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.J. Infect. Dis.192:24-29.
28. Boltz VF, Maldarelli F, Martinson N, Morris L, McIntyre JA, Gray G, Hopley MJ, Kimura T, Mayers DL, Robinson P, Mellors JW, Coffin JM, Palmer SE.2010.Optimization of allele-specific PCR using patientspecific HIV consensus sequences for primer design.J. Virol. Methods 164:122-126.
29. Boltz VF, Ambrose Z, Kearney MF, Shao W, KewalRamani VN, Maldarelli F, Mellors JW, Coffin JM.2012.Ultrasensitive allele-specific PCR reveals rare preexisting drug resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.J. Virol.86:12525-12530.
30. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR.2004.LigAmp for sensitive detection of single-nucleotide differences.Nat. Methods 1:141-147.
31. Dunbar SA.2006.Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection.Clin.Chim.Acta 363:71-82.
32. Houser B.2012.Bio-Rad's Bio-Plex suspension array system, xMAP technology overview.Arch.Physiol.Biochem.118:192-196.
33. Dowling WE, Kim B, Mason CJ, Wasunna KM, Alam U, Elson L, Birx DL, Robb ML, McCutchan FE, Carr JK.2002.Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants.AIDS 16:1809-1820.
34. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, Wong-Staal F.1985.Complete nucleotide sequence of the AIDS virus, HTLV-III.Nature 313:277-284.
35. Bortolin S, Black M, Modi H, Boszko I, Kobler D, Fieldhouse D, Lopes E, Lacroix JM, Grimwood R, Wells P, Janeczko R, Zastawny R.2004.Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms.Clin. Chem.50:2028-2036.
36. Li G, Luo X, He J, Zhu Z, Yu G, Qin H, Zeng T, Liu Z, Wu S, Xu J, Ren-Heidenreich L.2011.A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.Clin. Chem. Lab. Med.49:191-195.
37. Wadonda-Kabondo N, Bennett D, van Oosterhout JJ, Moyo K, Hosseinipour M, DeVos J, Zhou Z, Aberle-Grasse J, Warne TR, Mtika C, Chilima B, Banda R, Pasulani O, Porter C, Phiri S, Jahn A, Kamwendo D, Jordan MR, Kabuluzi S, Chimbwandira F, Kagoli M, Matatiyo B, Demby A, Yang C.2012.Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.Clin. Infect. Dis.54:S362-S368.
38. Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, Potter D, Mutsotso W, Borkowf CB, Mbori-Ngacha D, Muiruri P, Ong'ech JO, Zulu I, Njobvu L, Jetsawang B, Pathak S, Bulterys M, Shaffer N, Weidle PJ.2010.Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multicountry, prospective cohort study.PLoS Med.7:e1000233.doi:10.1371/journal.pmed.1000233.
39. Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, Tebas P, Bushman FD.2007.DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.Nucleic Acids Res.35:e91.doi:10.1093/nar/gkm435.
40. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM.2010.Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.J.Mol.Diagn.12:425-432.
41. Nicot F, Saliou A, Raymond S, Sauné K, Dubois M, Massip P, Marchou B, Delobel P, Izopet J.2012.Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.J. Clin. Virol.55:107-113.